Abstract:The recognition of invading pathogens and endogenous molecules from damaged tissues by toll-like receptors (TLRs) triggers protective self-defense mechanisms. However, excessive TLR activation disrupts the immune homeostasis by sustained pro-inflammatory cytokines and chemokines production and consequently contributes to the development of many inflammatory and autoimmune diseases, such as systemic lupus erythematosus (SLE), infection-associated sepsis, atherosclerosis, and asthma. Therefore, inhibitors/antagonists targeting TLR signals may be beneficial to treat these disorders. In this article, we first briefly summarize the pathophysiological role of TLRs in the inflammatory diseases. We then focus on reviewing the current knowledge in both preclinical and clinical studies of various TLR antagonists/inhibitors for the prevention and treatment of inflammatory diseases. These compounds range from conventional small molecules to therapeutic biologics and nanodevices. In particular, nanodevices are emerging as a new class of potent TLR inhibitors for their unique properties in desired bio-distribution, sustained circulation, and preferred pharmacodynamic and pharmacokinetic profiles. More interestingly, the inhibitory activity of these nanodevices can be regulated through precise nano-functionalization, making them the next generation therapeutics or "nano-drugs." Although, significant efforts have been made in developing different kinds of new TLR inhibitors/antagonists, only limited numbers of them have undergone clinical trials, and none have been approved for clinical uses to date. Nevertheless, these findings and continuous studies of TLR inhibition highlight the pharmacological regulation of TLR signaling, especially on multiple TLR pathways, as future promising therapeutic strategy for various inflammatory and autoimmune diseases.

Toll-like Receptors: Therapeutic Potential in Life Threatening Diseases- Cardiac Disorders

Toll-like receptors as potential therapeutic targets in cardiac dysfunction

Toll-like Receptors and Cardiac Diseases

The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease.

Toll-like Receptor and Its Roles in Myocardial Ischemic/reperfusion Injury

The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease

Toll like receptor - potential drug targets in infectious disease.

The Role of Toll-Like Receptor Signaling in the Progression of Heart Failure

Toll-like receptors in cardiac hypertrophy

Toll-Like Receptor 3 in Cardiovascular Diseases

From Molecular Mechanisms to Clinical Applications

Toll-Like Receptor 4 (TLR4) and AMPK Relevance in Cardiovascular Disease

Targeting Toll-Like Receptors With Small Molecule Agents

TLR-Mediated Signal Transduction and Neurodegenerative Disorders

Toll-like receptors in inflammation, infection and cancer

Regulatory T Lymphocytes in Myocardial Infarction: A Promising New Therapeutic Target

Toll-Like Receptor Signaling and Its Inducible Proteins

Role of Toll-Like Receptors in Neuroimmune Diseases: Therapeutic Targets and Problems

Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics.

The emerging role of Toll-like receptor 4 in myocardial inflammation

Toll-like Receptors: Emerging Targets of Immunomodulation